🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Phacogoniotomy in Medically-controlled POAG

RecruitingNAAges 40 Years - 85 YearsAllSun Yat-sen University
NCT06201455 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are: * Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG. * Whether the PEI+GT has value of health economics. Participants will be randomized to receive either PEI+GT or PEI+MED, and followed up with a 1-year period as a primary outcome.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. 40 ≤ Age ≤ 85 years, gender unrestricted. 2. Diagnosed with POAG. 3. Controlled IOP under 1 to 4 topical hypotensive medications, IOP ≤ 24 mmHg 4. Mean deviation (MD) for perimetry ≥ -16dB. 5. Presence of clinically significant cataract and best-corrected visual acuity measured using the ETDRS chart ≤ 0.63. 6. Voluntary participation of the patient in this study, signing an informed consent form, and agreeing to follow-up visits according to the study protocol. Exclusion Criteria: 1. Any history of intraocular surgery or ocular trauma. 2. Presence of other types of glaucoma, including primary angle-closure glaucoma and various forms of secondary glaucoma (e.g. secondary angle-closure, pigmentary, steroid-induced, angle-recession, neovascular, inflammatory, and pseudoexfoliation syndrome). 3. Presence of severe ocular diseases of various types that affect the acquisition of ocular parameters or interfere with perimetry. 4. Axial length \> 28 mm. 5. Monophthalmia (best-corrected visual acuity of the non-study eye \< 0.01). 6. Coexistence of severe systemic diseases affecting the entire body. 7. Pregnant or lactating women. * If both eyes of a patient meet the criteria, the eye with worse visual acuity will be selected for inclusion.
💊

What it tests

  • PEI+GT
  • PEI+MED
📍

Where

1 site
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy